BIOBANKING TO INNOVATION
Koh Furuta1, Hiroki Nakae2, Kazuhiko Okano3, Shin-ichiro Fujii4, Koichiro Yuji5, Yoshihito Nakajima6, Junko Ikeda2, Hiroyuki Kobayashi7, Naoko Shobayashi2, Tatsuaki Tsuruyama8, Hiroyuki Uchiyama9, Yasunari Yamanaka10
1. Kanagawa Cancer Center Hospital, Yokohama, Japan. 2. Japan Multiplex bio-Analysis Consortium, Tokyo, Japan. 3. Council for Industrial use of Biological and Environmental Repositories, Tokyo, Japan.
4. Bio-Medical Standards Group, National Metrology Institute of Japan National Institute of Advanced Industrial Science and Technology, Tsukuba, Japan. 5. Project Division of International Advanced Medical Research,Institute of Medical Science, the University of Tokyo, Tokyo, Japan. 6. LPD Marketing Manager, Thermo Fisher Scientific Japan, Tokyo, Japan. 7. Axcelead Drug Discovery Partners, Inc., Fuijisawa, Japan.
8. Department of Drug and Discovery Medicine, Pathology Division, Graduate School of Medicine, Kyoto University, Kyoto, Japan. 9. Nissui Pharmaceutical Co. Ltd., Tokyo, Japan. 10. RIKEN, Tsukuba, Japan

CIBER’s ROLESBACKGROUNDCIBER NETWORKS (TBD)

BACKGROUND
Accumulation of biospecimens andassociated data
Increased installation ofbiobanking facility

FACILITATIONFacilitate to access theaccumulated biospecimens andassociated data

Increased industrial
needs of bio specimens
and associated data
ISO 20387 Biotechnology— Biobanking — General
Requirements for
Biobanking

Biobanks in Japan needto link with each otherand network

National Center
Biobank
Network（NCBN）

INNOVATION

UNIV
Research
institutes

AMED networks
More efficientresearch anddevelopment inboth academia
and industry

CIBER PROSPECTUS★ Networking★

★Networking★
Medium size BB

Mega Biobanks

Small size BB

Prefectural

Univ

CEN
TER

Univ

CEN
TER

Private bb

PRI
VATE

PRI
VATE

PRI
VATE

PRI
VATE

Pharma製薬企業
製薬企業IVDcompanies
診断薬企業
診断薬企業

Pharmaceutical
Bio Tech
IVDs Companies

Researchers
研究者
研究者

Bio Tech
研究者
研究者★Users’ Forum & Center/Dissemination of information★

We can say that discussions shall be driven by users of biorepositories, notby providers. History indicates us again that innovations are with users oftechnologies. Although the precision medicine seems promising, somecritics point out that the precision medicine may produce medical divide.
One solution to these inputs could be to set up the opened framework of
biological and environmental repositories. Considering the roles ofbiological and environmental repositories, it is urgent for the current
generation to prepare and maintain this framework in a sustainable way.

Expertise

2018, January 22
FoundersBusinessPartners

Academia

CIBER’s BASIC PRINCIPLES

We, mainly users of biological and environmental repositories, decided tonetwork horizontally and further set up a corporation of “Council forIndustrial use of Biological and Environmental Repositories (CIBER)” tocommit to support a part of roles of medical infrastructure underinternational standards. Goal of a corporation of “Council for Industrial useof Biological and Environmental Repositories (CIBER)” is to support thesocial infrastructure without medical divide not only to ourselves but also
to our next generations.

BiobankNetwork★SOPs・Best Practices・Standards★
★Pipelines/bridging★

The direction of the current medical services in the world is towards theprecision medicine based on the genomic medicine. One of theinfrastructures of this environment is the storage and/or utilization ofbioresources including data. At this point in time, discussions regarding
standardization are started in the ISO framework. Some criticized thatstandardization is negative to progress in technologies. History tells us,
however, in some situation standardization may be positive to innovation if
direction of standardization is properly placed.

Along with declining birthrate and the following population aging, it iseasily assumed that public funds may not afford to provide supports to all
the social infrastructures. Under these circumstances, users of biologicaland environmental repositories as private partners are expected toparticipate to this framework in a proactive and pre-competitive manner.

InternationalCooperation

To support the marketIndustry

Medical Data
Biological Samples
KnowledgePublic(not-for-profit)

data

SupportPrimary
Data
Generation
Omics data

Government
Agencies

CONCLUSIONS

Based on ISBER model & BBMRI-ERIC model

Common Goods
Donation-baseResearchPartners

ExpertiseFunds

Diagnostics
Drug discovery

products

Private(profit)

SupportSOURCE: BBMRI-ERIC-Associated Expert Centres / Trusted Partners V2.0

https://ciber.or.jp/

The non-profit organization, CIBER, based in TokyoJapan supports the followings:
i. to facilitate setting up business models to meet theneeds of users/customers.
ii. to facilitate applying internationally common
platforms, standardized methods, and bestpractices.
iii.to facilitate setting up conformity assessment eco
system including self-assessment, contract, and/orcertification/ accreditation.
iv.to facilitate innovations in the biotechnology field.

Council for Industrial use of Biological and Environmental Repositories
Head Office Location: 6F Sanseido bldg. 2-4-10, Koujimachi, Chiyoda-ku, Tokyo 102-0083 JAPAN
Established in: January 22 2018
Chairperson: Koh Furuta M.D., Ph.D.
Contact: info@ciber.or.jp